Perspective Therapeutics (NYSEAMERICAN:CATX) Given “Buy” Rating at BTIG Research

Perspective Therapeutics (NYSEAMERICAN:CATX)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a research note issued on Wednesday, Benzinga reports. They currently have a $14.00 price target on the stock. BTIG Research’s price target would suggest a potential upside of 416.61% from the company’s previous close.

A number of other analysts also recently commented on CATX. William Blair began coverage on shares of Perspective Therapeutics in a report on Friday, September 18th. They set an “outperform” rating on the stock. BMO Capital Markets set a $11.00 target price on shares of Perspective Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, September 15th. Piper Sandler cut their target price on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Finally, Bank of America cut their target price on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $11.50.

Perspective Therapeutics Stock Up 10.2%

CATX stock traded up $0.25 during trading on Wednesday, reaching $2.71. 3,254,385 shares of the company were exchanged, compared to its average volume of 2,592,140. Perspective Therapeutics has a 52-week low of $1.96 and a 52-week high of $6.16. The stock’s 50 day moving average price is $2.95 and its 200 day moving average price is $3.40.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. On average, research analysts expect that Perspective Therapeutics will post -0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Abel Hall LLC acquired a new position in shares of Perspective Therapeutics in the first quarter valued at approximately $49,000. Caitong International Asset Management Co. Ltd acquired a new position in Perspective Therapeutics during the fourth quarter worth approximately $84,000. Wealth Effects LLC increased its position in Perspective Therapeutics by 32.0% during the first quarter. Wealth Effects LLC now owns 33,000 shares of the company’s stock worth $138,000 after purchasing an additional 8,000 shares during the last quarter. Quantinno Capital Management LP purchased a new stake in Perspective Therapeutics during the first quarter worth approximately $273,000. Finally, Taylor & Morgan Wealth Management LLC grew its stake in Perspective Therapeutics by 127.6% during the second quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock worth $225,000 after buying an additional 37,000 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

More Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: FDA grants Fast Track designation for PSV359. The designation supports expedited development and review of PSV359 for adults with advanced, unresectable or metastatic FAP-positive solitary fibrous tumors, a rare cancer with limited treatment options. It may enable more frequent FDA interactions and, if additional requirements are met, rolling review, Accelerated Approval or Priority Review. Early imaging data showed strong tumor uptake and rapid renal clearance. FDA Fast Track designation announcement
• Positive Sentiment: Analyst support remains strong. BTIG Research reaffirmed a Buy rating and assigned a $14 price target, implying substantial upside from recent trading levels. Across 11 brokerages, CATX has an overall Buy consensus, with nine Buy ratings and one Strong Buy rating. Analyst rating coverage
• Positive Sentiment: Additional clinical data is gaining visibility. Perspective’s [212Pb]VMT-α-NET data were accepted for presentation at the NANETS 2026 medical symposium, providing a potential future catalyst for its neuroendocrine tumor program. VMT-α-NET data presentation announcement
• Neutral Sentiment: Institutional positioning is mixed. In the latest reported quarter, 78 institutions increased holdings while 51 reduced them. BlackRock added shares, but several other large investors exited or cut positions, suggesting continued uncertainty around CATX’s valuation and clinical outlook.
• Negative Sentiment: Insider selling and clinical risk remain concerns. Reported insiders made seven open-market sales and no purchases during the past six months. Fast Track status does not guarantee approval, efficacy or commercial success; PSV359 is still in a Phase 1/2a trial, and the company warns that trials may be delayed, fail to produce meaningful results or require additional capital.

About Perspective Therapeutics

Perspective Therapeutics, Inc is a clinical-stage radiopharmaceutical biotechnology company developing precision-targeted alpha therapies for cancer. The company’s approach combines tumor-targeting molecules with radioactive isotopes to deliver highly focused radiation to cancer cells while limiting exposure to surrounding healthy tissue.

Perspective’s proprietary VMT platform is designed to support both diagnostic imaging and therapeutic applications. Its lead programs include VMT-α-NET, an investigational therapy targeting somatostatin receptor 2 for patients with neuroendocrine tumors, and VMT01, an investigational program targeting melanocortin 1 receptor-expressing cancers, including certain metastatic melanomas.